Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences.
By D. Sanglard, F. Odds. Lancet. Infectious Diseases (Print), 2002
811 citations recorded by the source corpus.
Subfields: Epidemiology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/4116b488e69eeefe4bcb6810ded57a0cb8d80db2
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Infectious Diseases
Citations in the corpus
- Activity of phenolic compounds from plant origin against Candida species (2015, background): “…among other important biological components with a direct interference on drug resistance, is crucial (Franz et al., 1998; Kanafani and Perfect, 2008; Lupetti et al., 2003; Mayer et al., 2013; Noël, 2012; Perlin, 2014; Sangamwar et al., 2008; Sanglard and Odds, 2002; White et al., 2002, 1998).”
- Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. (2012, background): “…mechanism by which Candida species resist the effects of azole antifungals involves the active efflux of the drug out of the cell via the activation of two kinds of efflux transport proteins encoded by either MDR or CDR genes (Lupetti et al., 2002; Ghannoum & Rice, 1999; Sanglard & Odds, 2002).”
- Resistance to Antifungal Agents: Mechanisms and Clinical Impact (2008, background): “Azole-resistant C. albicans is less common among patients with other diseases, such as vaginal candidiasis [45] and can-didemia [46].”
- Candida parapsilosis, an Emerging Fungal Pathogen (2008, background): “While some favor the argument that it has (16), it should be noted that others conclude that azole usage has not influenced the prevalence of certain Candida species causing infections (244).”
- Epidemiology and Predictors of Mortality in Cases of Candida Bloodstream Infection: Results from Population-Based Surveillance, Barcelona, Spain, from 2002 to 2003 (2005, background): “Malignancy 123 (36) 61 (35) 6 (20) 18 (58) 9 (75) 21 (27) Immunosuppressive therapy 130 (39) 64 (37) 6 (21) 16 (53) 9 (75) 29 (38) Neutropenia 38 (11) 10 (6) 0 8 (26) 8 (67) 9 (12) Renal failure 117 (34) 72 (41) 11 (38) 11 (36) 3 (25) 16 (21) Transplant patient 26 (8) 3 (2) 0 5 (15) 2 (17) 12 (15) H”
- Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program (2004, background): “Race White 293 (57) 313 (50) 136 (49) 60 (43) 91 (59) 606 (53) Black 190 (37) 280 (45) 126 (46) 79 (56) 52 (34) 470 (41) Other or unknown 33 (6) 33 (5) 13 (5) 2 (1) 10 (7) 67 (6)”